Purple Biotech (PPBT) Consolidated Net Income (2014 - 2026)

Purple Biotech (PPBT) has reported Consolidated Net Income for 13 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Consolidated Net Income rose 67.05% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $27.7 million (up 310.75% YoY), while the FY2025 annual figure was -$26.5 million, down 263.0% from the prior year.
• Consolidated Net Income eased to $2.2 million in Q1 2026 per PPBT's latest filing, from $23.2 million in the prior quarter.
• Across five years, Consolidated Net Income topped out at $23.2 million in Q4 2025 and bottomed at $629000.0 in Q4 2024.
• Historically, Consolidated Net Income has averaged $4.6 million across 5 years, with a median of $3.4 million in 2022.
• Annual changes were most pronounced in 2022 — Consolidated Net Income soared 172600.0% — and 2024, when it plunged 77.29%.
• Purple Biotech's Consolidated Net Income stood at $6.0 million in 2022, then plunged by 53.89% to $2.8 million in 2023, then slumped by 77.29% to $629000.0 in 2024, then surged by 3580.92% to $23.2 million in 2025, then sank by 90.5% to $2.2 million in 2026.
• Business Quant data shows PPBT's Consolidated Net Income at $2.2 million in Q1 2026, $23.2 million in Q4 2025, and $1.2 million in Q3 2025.